Abstract
Parallel administration of the proton pump inhibitor (PPI) esomeprazole has been shown to decrease oral bioavailability of posaconazole in healthy volunteers. We prospectively analyzed serum samples (n = 59) obtained from hematology patients (n = 27) under posaconazole prophylaxis. Patients treated concomitantly with pantoprazole had significantly lower posaconazole levels than patients without PPI treatment (median levels of 630 μg/liter versus 1,125 μg/liter, respectively). These results suggest that drug monitoring is relevant when posaconazole and pantoprazole are administered concomitantly. Copyright © 2010, American Society for Microbiology. All Rights Reserved.
| Original language | English |
|---|---|
| Journal | Antimicrobial Agents and Chemotherapy |
| Volume | 54 |
| Issue number | 9 |
| Pages (from-to) | 4029-4032 |
| Number of pages | 4 |
| ISSN | 0066-4804 |
| DOIs | |
| Publication status | Published - 09.2010 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research areas and keywords
- Chemistry
- Adult
- Aged
- Antifungal Agents
- Chromatography, High Pressure Liquid
- Female
- Hematologic Neoplasms
- Humans
- Male
- Middle Aged
- Mycoses
- Prospective Studies
- Triazoles
ASJC Scopus Subject Areas
- Pharmacology
- Infectious Diseases
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver